首页> 外文期刊>Genes, Chromosomes and Cancer >Identification of novel deletion regions on chromosome arms 2q and 6p in breast carcinomas by amplotype analysis.
【24h】

Identification of novel deletion regions on chromosome arms 2q and 6p in breast carcinomas by amplotype analysis.

机译:通过双倍型分析鉴定乳腺癌染色体臂2q和6p上的新缺失区。

获取原文
获取原文并翻译 | 示例
           

摘要

DNA fingerprinting by arbitrarily primed PCR (AP-PCR) was employed to identify molecular genetic alterations in 37 primary breast carcinomas. AP-PCR is a PCR-based technique that uses only one primer of arbitrary sequence that generates a molecular karyotype (amplotype) of tumors. The breast cancer amplotype generated with two arbitrary primers (MCG1 and Blue) showed a relatively high frequency (more than 20% of the tumors) of gains at chromosomes 1, 4, and 8, and of losses at chromosomes 2, 4, 6, 9, 10, 11, 13, and the X chromosome. We further analyzed the regions most commonly gained at chromosome 8 (47%) and lost at chromosomes 2 (38%) and 6 (49%) by determining the subchromosomal localization of the fingerprint bands from these chromosomes. The region of gain at chromosome 8 was mapped at 8q24.1, close to MYC. Band MCG1-A1 was assigned to chromosome band 2q22, and band Blue-J was assigned to 6p21. Common losses of these chromosomal regions have not been described for breast cancer. To map these deletion regions more precisely, we performed loss of heterozygosity (LOH) analysis by microallelotyping on 20 of the 37 cancers previously analyzed by AP-PCR and another additional 52 breast carcinomas. The results suggest that the regions at 2q21-24 and 6p21-23 may harbor novel tumor suppressor genes for breast cancer. LOH at 2q21-24 (D2S2304) was more frequent in high-grade tumors (59%) than in low-grade tumors (29%) (P = 0.03). This suggests that this genetic alteration may be associated with tumor progression and shows the power of the amplotype approach in detecting novel genetic alterations that are useful as clinical parameters of breast cancer. Copyright 2000 Wiley-Liss, Inc.
机译:通过任意引物PCR(AP-PCR)进行DNA指纹识别,以鉴定37例原发性乳腺癌的分子遗传学改变。 AP-PCR是一种基于PCR的技术,仅使用一个任意序列的引物即可产生肿瘤的分子核型(两性型)。用两种任意引物(MCG1和蓝色)生成的乳腺癌单倍体在染色体1、4和8处获得相对较高的频率(占肿瘤的20%),在染色体2、4、6处具有相对较高的频率。 9、10、11、13和X染色体。通过确定来自这些染色体的指纹带的亚染色体定位,我们进一步分析了在8号染色体上最常见的区域(47%)和在2号染色体上丢失的区域(38%)和6号区域丢失的区域(49%)。染色体8的增益区域定位在8q24.1,接近MYC。将MCG1-A1频段分配给2q22染色体,将Blue-J频段分配给6p21。这些染色体区域的常见损失尚未描述为乳腺癌。为了更精确地定位这些缺失区域,我们通过微变型分型对先前通过AP-PCR分析的37种癌症中的20种以及另外52种乳腺癌进行了杂合性缺失(LOH)分析。结果表明,在2q21-24和6p21-23区域可能具有新颖的乳腺癌抑癌基因。高等级肿瘤(59%)中2q21-24(D2S2304)的LOH频率比低等级肿瘤(29%)高(P = 0.03)。这表明该遗传改变可能与肿瘤进展有关,并显示了单倍型方法在检测可用作乳腺癌临床参数的新型遗传改变中的作用。版权所有2000 Wiley-Liss,Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号